Safety of cangrelor and transition to oral P2Y
Acute coronary syndrome
Bleeding
Cangrelor
P2Y12 receptor inhibitor
Percutaneous coronary intervention
Journal
European heart journal open
ISSN: 2752-4191
Titre abrégé: Eur Heart J Open
Pays: England
ID NLM: 9918282081406676
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
16
05
2023
revised:
04
07
2023
accepted:
01
08
2023
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
Cangrelor is the only intravenous P2Y Adult patients with ACS undergoing percutaneous coronary intervention (PCI) receiving cangrelor were included in the study. Patients were followed for 30 days. Incidence of bleeding events, major adverse cardiac events, and transition strategy to oral P2Y The use of cangrelor in ACS patients undergoing PCI and the transition strategy to P2Y
Identifiants
pubmed: 37646045
doi: 10.1093/ehjopen/oead076
pii: oead076
pmc: PMC10462400
doi:
Types de publication
Journal Article
Langues
eng
Pagination
oead076Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: All the activities were funded by Chiesi Farmaceutici S.p.A. (Parma, Italy).
Références
Lancet. 2013 Dec 14;382(9909):1981-92
pubmed: 24011551
Circulation. 2020 Aug 4;142(5):441-454
pubmed: 32795098
Herz. 2018 Dec;43(8):689-694
pubmed: 30456630
Cardiol Rev. 2017 May/Jun;25(3):133-139
pubmed: 28379902
N Engl J Med. 2013 Jul 25;369(4):393-4
pubmed: 23883387
Expert Rev Cardiovasc Ther. 2019 Oct;17(10):717-727
pubmed: 31583920
Circ Cardiovasc Interv. 2019 Jul;12(7):e007342
pubmed: 31296081
JACC Cardiovasc Interv. 2017 Jan 23;10(2):121-129
pubmed: 28104204
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Panminerva Med. 2022 Mar;64(1):9-16
pubmed: 34060281
Circulation. 2022 Jan 18;145(3):e4-e17
pubmed: 34882436
J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16
pubmed: 17418288
Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):441-52
pubmed: 25414322
Nat Rev Cardiol. 2013 Mar;10(3):121-2
pubmed: 23319096
Am Heart J. 2012 May;163(5):768-776.e2
pubmed: 22607853
J Am Heart Assoc. 2021 Jul 6;10(13):e022125
pubmed: 34212768
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
J Thromb Thrombolysis. 2015 Oct;40(3):317-22
pubmed: 26024789
J Am Coll Cardiol. 2016 Feb 9;67(5):596-8
pubmed: 26846956
JACC Cardiovasc Interv. 2016 Sep 26;9(18):1905-13
pubmed: 27659566
J Cardiovasc Med (Hagerstown). 2017 Aug;18(8):580-589
pubmed: 28639987
J Am Coll Cardiol. 2023 Feb 14;81(6):537-552
pubmed: 36754514
Clin Cardiol. 2022 Sep;45(9):913-920
pubmed: 35733352
Circulation. 2019 Apr 2;139(14):1661-1670
pubmed: 30630341
N Engl J Med. 2013 Apr 4;368(14):1303-13
pubmed: 23473369
JACC Cardiovasc Interv. 2015 Mar;8(3):436-446
pubmed: 25703883
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1712-1714
pubmed: 28838482
JACC Cardiovasc Interv. 2010 Jun;3(6):571-83
pubmed: 20630450
J Am Coll Cardiol. 2017 Jan 31;69(4):463-464
pubmed: 27914699
J Am Heart Assoc. 2022 Jun 7;11(11):e024513
pubmed: 35621210
JACC Cardiovasc Interv. 2015 Mar;8(3):424-433
pubmed: 25703887
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):151-157
pubmed: 30698669
Nat Rev Cardiol. 2022 Feb;19(2):117-132
pubmed: 34426673
EuroIntervention. 2023 Mar 20;18(15):1266-1268
pubmed: 36512429
Eur Heart J Acute Cardiovasc Care. 2019 Feb;8(1):39-44
pubmed: 28574274
J Interv Cardiol. 2015 Oct;28(5):415-9
pubmed: 26381736
Am J Cardiol. 2017 Aug 1;120(3):359-361
pubmed: 28576266